An interventional study of Neuronavigation-Guided Stereotactic Hematoma Aspiration and Tenecteplase in Primary Pontine Hemorrhage, sponsored by Beijing Tiantan Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Beijing Tiantan Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This multicenter, randomized, open-label, blinded-endpoint clinical study aims to evaluate the safety, feasibility, and potential clinical benefits of neuronavigation-guided stereotactic hematoma aspiration combined with tenecteplase in patients with acute primary brainstem hemorrhage.A total of 140 patients will be randomly assigned in a 1:1 ratio to receive either stereotactic hematoma aspiration combined with tenecteplase and standard medical treatment or standard medical treatment alone.The primary outcome is the proportion of patients with a Glasgow Coma Scale (GCS) score greater than 8 at 90 days. Safety outcomes include mortality, symptomatic rebleeding, and intracranial infection.
Beijing Tiantan Hospital is the lead sponsor of 493 studies on the registry; 297 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive neuronavigation-guided stereotactic hematoma aspiration followed by intralesional tenecteplase administration, in addition to standard medical treatment.
Procedure: Neuronavigation-Guided Stereotactic Hematoma Aspiration · Drug: Tenecteplase · Other: Standard Medical Treatment
Other: Standard Medical Treatment
Neuronavigation-guided stereotactic hematoma aspiration and catheter drainage will be performed within 6 hours after randomization.
Tenecteplase (0.155 mg per dose) will be administered into the hematoma cavity through the drainage catheter after postoperative CT confirms hematoma stability, for up to three doses.
Also known as: rhTNK-tPA
Standard medical treatment includes blood pressure management, intracranial pressure management, respiratory support, nutritional support, and rehabilitation.
Proportion of Participants With GCS Score >8
Proportion of participants with a Glasgow Coma Scale (GCS) score greater than 8 at 90 days.
Time frame: 90 days after randomization
All-Cause Mortality
Proportion of participants who die from any cause within 30 days after randomization.
Time frame: Within 30 days after randomization.
7-Day All-Cause Mortality
Time frame: Within 7 days
Symptomatic Rebleeding
Time frame: Within 72 hours after tenecteplase administration
Intracranial Bacterial Infection
Time frame: Within 30 days
Serious Adverse Events (SAEs)
Time frame: Within 30 days
Adverse Events (AEs)
Time frame: Within 30 days
Serious Adverse Events (SAEs)
Time frame: Within 365 days
Adverse Events (AEs)
Time frame: Within 365 days
Proportion With GCS Increase ≥3 Points
Time frame: 30 days
Proportion With Recovery of Consciousness
Time frame: 30 days
Proportion With mRS 0-3
Time frame: 90 days
Proportion With mRS 0-3
Time frame: 365 days
Change in GCS Score Over Time
Time frame: From baseline through 90 days after randomization
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2026 (actual). Primary completion is estimated for Dec 2028, 32 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tenecteplase